BioSpace News Archive

Now that school is back in session, it’s never too early to start thinking about an internship program for summer breaks. Use these steps to secure one for yourself.

Amicus Therapeutics, headquartered in Cranbury, New Jersey, inked a definitive agreement for 10 gene therapy programs licensed from Nationwide Children’s Hospital through the acquisition of Celenex.

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

The two biggest areas for biotech startups in the U.S. are Cambridge in Boston and the San Francisco Bay Area. They’re also the locations of astonishingly expensive real estate. But they’re where biotechs seem to want to be because they’re close to talent, academic research institutions, and the attention of venture capital.

China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.

LineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines.

New York-based Y-mAbs Therapeutics will look at securing $96 million through an initial public offering to support development of its antibody-based therapeutic treatments for cancer.

Shares of OncoMed Pharmaceuticals are falling this morning after the company announced that Celgene has walked away from a deal to license the company’s bispecific antibody navicixizumab.

In the biotech hub area known as Pharm Country, the small state of Rhode Island often gets overlooked in favor of its larger neighbors, such as New York, New Jersey and Pennsylvania. But, the Ocean State is making some moves to enhance its image as a biotech hub, particularly in the wake of some lost jobs.

Shares of Molecular Templates are up more than 52 percent in premarket trading after the company announced it has struck a deal with pharma giant Takeda Pharmaceuticals.